The thesis
channel-pullback is a mean-reversion play with a trend filter. It buys pullbacks to the lower regression channel or volume support — but only inside confirmed uptrends — and exits at the upper channel or overhead resistance. The idea is to harvest the noise around a rising trend rather than bet on the trend itself. It trades a 24-name large-cap universe spanning tech, financials, healthcare, staples, and energy, and is currently live.
Recent activity
The last two weeks show the strategy behaving as designed: small, selective, and patient. Scheduled runs executed one or two trades on active days and zero on quiet ones (Aug 10 and Aug 11 both passed with no fills). The clearest fingerprint of the approach is BAC: sold at 63.12 on Aug 7, then rebought 31 shares at 62.98 on Aug 6 and again at 64.07 on Aug 13 — textbook pullback re-entries. CAT and PG show the same round-trip rhythm.
Less encouraging is the equity line. Portfolio total drifted from $9,876 on Aug 7 to $9,712 on Aug 13, a soft patch that coincides with the strategy staying invested through choppy conditions. It is a small sample, but the recent tape has not rewarded the pullback buys.
Backtest and validation
On paper the record is respectable but unspectacular: 7.62% total return, 4.19% CAGR, Sharpe 0.40, and a 14.83% max drawdown across 451 days and 137 trades. The win rate is just 39.4%, so the edge relies on winners outsizing losers — always a fragile profile. Turnover of 2,311% is very high; fees stay modest at $137 only because per-trade costs are low, but the frequency is a standing tax on returns.
The more important verdict comes from walk-forward validation, and it is a fail. Three of four folds were positive — Fold 3 was outstanding (+20.68%, Sharpe 3.86) — but Fold 2 collapsed to −11.42% with a −1.70 Sharpe and a 16% drawdown. That single regime break is the whole story: the strategy is not robustly stationary. The deflated Sharpe ratio of 0.196 and out-of-sample Sharpe of 0.74 against a full-sample 0.40 suggest the headline numbers lean on one strong window. A PSR of 0.702 across 7 trials is borderline, not convincing.
The balance
Strengths: the logic is coherent, trades are disciplined and selective, and the best folds show real upside when the regime cooperates. Risks: a sub-40% win rate, a validation fail driven by a badly negative fold, a low deflated Sharpe, and punishing turnover. This is a strategy that works in trending, orderly markets and gives much of it back when the channel structure breaks.
Running it live is defensible as a data-gathering exercise, but the validation flags argue against sizing it up. The number to watch is whether the current soft patch resolves like Fold 4 (a shallow +3.63%) or like Fold 2. Until it strings together out-of-sample folds without a blow-up, channel-pullback earns a hold, not a promotion.